Our Technology Platform

Three scientific innovations. One goal: unlocking brain repair.

  • Synap Biotech is developing intranasal VHH therapeutics designed to unlock the brain's natural capacity for repair following stroke and other neurological injuries.

    Our approach combines three complementary innovations:

    • Validated biology by targeting Nogo-A and related inhibitory pathways that suppress neuroplasticity.

    • Intranasal delivery designed to bypass the blood-brain barrier and improve CNS exposure.

    • A multispecific VHH platform engineered to address multiple biological barriers to neurological recovery.

    Together, these innovations are designed to promote axonal regeneration, enhance neuroplasticity, and restore neurological function during the critical early recovery window.

Vailidated Biology

Natural Suppression

  • Following stroke and other neurological injuries, proteins such as Nogo-A suppress the brain's natural ability to reorganize and repair damaged neural networks.

    This biological brake limits axonal regeneration and neuroplasticity, reducing the brain's capacity for functional recovery even after successful rehabilitation.

    Decades of preclinical research have shown that blocking Nogo-A can significantly enhance neurological recovery across multiple models of CNS injury.

Intranasal Delivery

Bypassing the BBB

  • Effective treatment of neurological disorders requires therapeutic agents to reach the brain.

    Synap's intranasal delivery strategy is designed to bypass the blood-brain barrier, enabling direct access to the central nervous system without invasive procedures.

    Potential advantages include:

    • Non-invasive administration

    • Designed to improve CNS exposure

    • Potential for at-home treatment

    • Improved patient convenience and adherence

Multispecific VHH Platform

A Smarter Therapeutic

  • Synap is developing multispecific VHH therapeutics designed to block Nogo-A and related inhibitory pathways that restrict neurological recovery.

    Our VHH platform offers several important advantages:

    • Small and highly engineerable

    • Stable and well suited for intranasal delivery

    • Capable of targeting multiple biological pathways within a single construct

    • Efficient manufacturing and scalability